Prime Medicine (PRME) Focuses on Liver Franchise With $191.4M Cash Runway

Prime Medicine Inc. (NASDAQ:PRME) is one of the best new penny stocks to buy. On March 3, Prime Medicine reported its full-year 2025 financial results, highlighting a shift toward its in vivo liver franchise. The company ended the year with $191.4 million in cash, cash equivalents, and investments, providing a financial runway into 2027. Despite a net loss of $201.1 million for the year, R&D expenses remained relatively stable at $160.6 million as the company optimized its workforce and deprioritized its Chronic Granulomatous Disease/CGD program to focus on high-priority clinical milestones.

The company is advancing toward key regulatory filings for its lead liver-focused programs in Wilson Disease/WD and Alpha-1 Antitrypsin Deficiency/AATD. Prime Medicine remains on track to submit an IND or CTA for the WD program in H1 2026, followed by a mid-2026 submission for the AATD program. Initial clinical data for both indications are expected in 2027. Additionally, the company is progressing its Cystic Fibrosis program with support from the Cystic Fibrosis Foundation and continues its CAR-T partnership with Bristol Myers Squibb.

Prime Medicine (PRME) Focuses on Liver Franchise With $191.4M Cash Runway

Photo by RephiLe water on Unsplash

Regarding its CGD candidate, PM359, Prime Medicine Inc. (NASDAQ:PRME) is actively engaging with the FDA to pursue an accelerated approval pathway. This follows the publication of positive Phase 1/2 data in the New England Journal of Medicine, which showed durable restoration of enzyme activity and early clinical benefits. The company intends to submit a BLA once final alignment with the FDA is reached, potentially making PM359 the first Prime Edited therapy available to patients.

Prime Medicine Inc. (NASDAQ:PRME) is a biotechnology company that delivers genetic medicines to address the spectrum of diseases by deploying gene editing technology in the US.

While we acknowledge the risk and potential of PRME as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than PRME and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 40 Most Popular Stocks Among Hedge Funds Heading Into 2026 and Goldman Sachs Value Stocks: 10 Stocks to Buy.

Disclosure: None. Follow Insider Monkey on Google News.